Results 141 to 150 of about 101,340 (329)

A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.

, 1988
Christiane Mendre, Meghan Rodriquez, Christiane Gueudet, MARIE‐FRANÇOISE LIGNON, Marie‐Christine Galas, Jeanine Laur, P. Worms, Jean Martínez   +7 more
openalex   +1 more source

Dopaminergic Regulation of Progesterone Receptors: Brain D5 Dopamine Receptors Mediate Induction of Lordosis by D1-Like Agonists in Rats [PDF]

, 1996
Ede Marie Apostolakis, János Garai, Charles A. Fox, C. Smith, Stanley J. Watson, James H. Clark, Bert W. O’Malley   +6 more
openalex   +1 more source

The Persistence of Dopamine Dysregulation Syndrome after Pallidal Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dopamine dysregulation syndrome (DDS) is a debilitating complication of Parkinson's disease (PD) dopamine replacement therapy (DRT) in which patients pathologically and/or compulsively use dopaminergic drugs to treat motor symptoms. Studies examining DDS outcomes following deep brain stimulation (DBS) are limited and have focused on
Natalie David, Stewart A. Factor, Richa Tripathi, Lenora Higginbotham   +3 more
wiley   +1 more source

Metabolic effects of prolactin and the role of dopamine agonists: A review. [PDF]

Front Endocrinol (Lausanne), 2022
Kirsch P, Kunadia J, Shah S, Agrawal N.
europepmc   +1 more source

Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors [PDF]

, 1995
Kevin D. Burris, Mary A. Pacheco, Theresa M. Filtz, Mei‐Ping Kung, Hank F. Kung, Perry B. Molinoff   +5 more
openalex   +1 more source

Health‐Related Quality of Life in Relation to the 5‐2‐1 Criteria in Parkinson's Disease in Sweden

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Device‐aided therapies (DAT) offer alternatives to oral or transdermal dopaminergic treatments in advanced Parkinson's disease (PD), where they can reduce motor fluctuations and dyskinesia and improve health‐related quality of life (HRQoL).
Frida Hjalte, Anna Gustafsson, Jenny Samuelsson, Filip Bergquist, Anders Johansson, Per Odin   +5 more
wiley   +1 more source

Incident mental health episodes after initiation of gabapentinoids vs. dopamine agonists for early-onset idiopathic restless legs syndrome. [PDF]

Psychiatry Res, 2023
Costales B, Vouri SM, Brown JD, Setlow B, Goodin AJ.   +4 more
europepmc   +1 more source

Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine

, 1988
E. Ciccarelli, R. Touzel, Michael Besser, A. Grossman   +3 more
openalex   +1 more source

The agonist activities of the putative antipsychotic agents, L‐745,870 and U‐101958 in HEK293 cells expressing the human dopamine D_4.4 receptor [PDF]

, 1998
Lucien Gazi, Ionel Bobirnac, M Danzeisen, E. Schüpbach, Anne T. Bruinvels, Sabine Geisse, Bernd Sommer, Daniël Hoyer, Mark D. Tricklebank, Philippe Schoeffter   +9 more
openalex   +1 more source

Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sacha Brohée, Emmanuel Roze, David Grabli, Hélène Letrillart, Lise Mantisi, Cendrine Foucard, Elodie Hainque, Florence Cormier, Aurélie Méneret, Fabien Hauw   +9 more
wiley   +1 more source